Immunogenic HAV peptides

Synthetic peptides, containing amino acid residues 15 to 21, 75-80 and 101-107 of the hepatitis A virus (HAV) VP1 structural protein sequence, was prepared and chemically conjugated to a protein carrier molecule. The peptide-carrier conjugate, when inoculated into test animals, gives rise to a speci...

Full description

Saved in:
Bibliographic Details
Main Authors BOGER; JOSHUA S, EMINI; EMILIO A, HUGHES; JOSEPH V
Format Patent
LanguageEnglish
Published 24.06.1986
Edition4
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Synthetic peptides, containing amino acid residues 15 to 21, 75-80 and 101-107 of the hepatitis A virus (HAV) VP1 structural protein sequence, was prepared and chemically conjugated to a protein carrier molecule. The peptide-carrier conjugate, when inoculated into test animals, gives rise to a specific anti-peptide IgG antibody response. These anti-peptide antibodies bind directly to intact hepatitis A virions, bind to purified and denatured VP1, compete with polyspecific antibody derived from human HAV immune sera, and are capable of neutralizing the infectivity of the virus. The peptide is useful as a synthetic subunit immunogen that stimulates an immune response against HAV.
Bibliography:Application Number: US19840649388